基于PLGA的纳米颗粒用于结直肠癌免疫疗法:当前的概念和未来的前景
Yuhan Wang1, Peng Huang2, Chun Li1
1Department of General Surgery, Zigong Fourth People's Hospital, Zigong, Sichuan, China.
Frontiers in pharmacology
|November 13, 2025
概括
聚 (乳糖-co-甘油酸) (PLGA) 纳米颗粒可以通过重塑瘤微环境来增强结直肠癌 (CRC) 免疫疗法. 这些智能输送系统改善了药物向和免疫反应,为患者提供了新的希望.
科学领域:
- 在瘤学瘤学.
- 纳米技术 纳米技术
- 免疫学 免疫学 免疫学
背景情况:
- 大肠直肠癌 (CRC) 是癌症死亡的主要原因.
- 目前的免疫疗法,如检查点抑制剂,只能使CRC患者的一小部分受益 (dMMR/MSI-H).
- 免疫抑制性瘤微环境 (TME) 限制了治疗的有效性,需要改造它的策略.
研究的目的:
- 审查用于结直肠癌免疫治疗的Poly (乳酸-co-甘油酸) (PLGA) 纳米颗粒的使用原则.
- 要突出PLGA纳米颗粒如何克服免疫抑制性TME并增强抗瘤免疫力.
- 讨论临床应用的翻译考虑.
主要方法:
- 关于PLGA纳米粒子在CRC免疫疗法中的应用现有文献的综述.
- 强调有效载荷选择,释放动力学和准策略.
- 讨论安全性,药理动力学,可制造性和监管方面的问题.
主要成果:
- 在CRC中,PLGA纳米粒子作为免疫调节剂的多功能载体.
- 这些平台可以增强抗原呈现,并在TME内重新调整髓状细胞.
- 协调分娩与检查点封锁可以加强抗瘤免疫力并抑制瘤生长.
结论:
- 基于PLGA纳米粒子的策略显示出改善CRC免疫疗法的前景.
- 优化有效载荷,释放,向和解决翻译因素是临床成功的关键.
- 这些进展可能会将免疫治疗的好处扩展到更广泛的CRC患者中.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K


